Alanine for Liver Function (ALT — Alanine Aminotransferase)

Alanine aminotransferase (ALT, historically SGPT) is the single most-ordered biomarker on every standard liver panel in clinical medicine worldwide. The enzyme is named after alanine because it catalyzes the central transamination between alanine and alpha-ketoglutarate to produce pyruvate and glutamate — the entry step into hepatic gluconeogenesis. ALT is present at extraordinarily high concentrations inside hepatocytes (roughly 3,000-fold higher than serum levels) and at very low concentrations in all other tissues. The combination of liver-specific localization and high intracellular concentration makes serum ALT the most sensitive routine biochemical marker of hepatocyte injury: even modest liver-cell damage releases enough enzyme to produce measurable serum elevations. The 21st-century transformation of population liver disease — the global emergence of non-alcoholic fatty liver disease (NAFLD), now affecting approximately a quarter of all adults worldwide — has elevated ALT from a hepatology workup tool to a routine population health screen for metabolic dysfunction. This page covers the biochemistry of ALT, the interpretation of ALT elevation patterns, the AST:ALT ratio in distinguishing different liver pathologies, modern healthy-range cutoffs, NAFLD epidemiology, drug-induced liver injury, and the practical workup of an isolated ALT elevation.

Table of Contents

  1. ALT — The Enzyme Named After Alanine
  2. Why ALT Is the Most Liver-Specific Routine Marker
  3. The Normal Range Controversy (40 U/L vs 19/30 U/L)
  4. Interpretation by Magnitude of ALT Elevation
  5. The AST:ALT Ratio — Alcoholic vs Non-Alcoholic Patterns
  6. NAFLD — The Global Liver Disease Epidemic
  7. Drug-Induced Liver Injury (DILI)
  8. Viral Hepatitis Pattern
  9. Practical Workup of an Isolated ALT Elevation
  10. The Alanine Load Test for Hepatic Function
  11. Cautions
  12. Key Research Papers
  13. Connections

ALT — The Enzyme Named After Alanine

Alanine aminotransferase (ALT, EC 2.6.1.2) is one of the two principal aminotransferases of clinical interest, the other being aspartate aminotransferase (AST, EC 2.6.1.1, historically SGOT). Both enzymes use pyridoxal-5-phosphate (the active form of vitamin B6) as cofactor and catalyze reversible transamination reactions. ALT catalyzes:

L-alanine + alpha-ketoglutarate ↔ pyruvate + L-glutamate

This is the rate-limiting entry step for alanine's contribution to hepatic gluconeogenesis. In muscle, ALT runs the same reaction in the forward direction (consuming pyruvate and glutamate to produce alanine for nitrogen export); in liver, it runs in reverse (consuming alanine to produce pyruvate for gluconeogenesis). The directional preference depends on cell-specific concentrations of the four reactants and on the cell's gluconeogenic vs gluconeogenic-suppressed state.

ALT exists in two isozymic forms in humans: ALT1 (cytosolic, encoded by GPT) and ALT2 (mitochondrial, encoded by GPT2). The cytosolic ALT1 is the predominant form in liver and the form that is measured on standard liver panels. The mitochondrial ALT2 is more highly expressed in muscle, heart, and brain — tissues where the alanine-shuttle role is less critical — and contributes only modestly to serum activity in healthy adults.

The historical name SGPT (serum glutamic-pyruvic transaminase) reflects the products of the reaction (glutamate and pyruvate) rather than the substrate (alanine). The shift to the ALT nomenclature occurred gradually through the 1980s and 1990s as the systematic IUPAC enzyme nomenclature became the international standard. Older patients and some European laboratories may still report SGPT; this is the same enzyme as ALT.

Back to Table of Contents

Why ALT Is the Most Liver-Specific Routine Marker

ALT's clinical usefulness depends on two facts:

AST is the more revealing contrast. AST is also abundant in liver, but is equally abundant in skeletal muscle, cardiac muscle, kidney, brain, and red blood cells. Hemolysis during phlebotomy can artifactually elevate AST. Vigorous exercise can elevate AST significantly. Acute myocardial infarction historically caused dramatic AST elevations (which is why AST was originally used as a cardiac marker before cardiac-specific troponins came along). All of these confounders are absent or markedly reduced for ALT.

The clinical inference is that an isolated ALT elevation almost always reflects hepatocyte injury, while an AST elevation must always be interpreted in light of possible non-hepatic sources. This is the basis for the diagnostic primacy of ALT in hepatology workups and for the AST:ALT ratio as a discriminator (see below).

There are a few specific exceptions worth mentioning:

Back to Table of Contents

The Normal Range Controversy (40 U/L vs 19/30 U/L)

The standard laboratory "normal range" for ALT is typically reported as up to 40 U/L (some labs use up to 35 U/L). These ranges were originally derived in the 1970s from blood donor populations that, in retrospect, included many subjects with subclinical NAFLD and chronic viral hepatitis (then unrecognized). The result is that the "normal range" was set too high — many subjects within the reported normal range actually had liver pathology.

The Prati 2002 Annals of Internal Medicine study redefined healthy ALT ranges using a much more rigorously screened reference population (blood donors with no clinical or laboratory evidence of liver disease, no BMI above 25, no metabolic syndrome). The Prati cutoffs are:

The Prati cutoffs have not been universally adopted by clinical laboratories, partly because the implications are uncomfortable: applying the stricter cutoffs to the general population reclassifies a substantial fraction of presumably-healthy adults as having mildly abnormal ALT. The NHANES population data show that roughly 20-30% of US adults have ALT above the Prati upper limit, which corresponds well to the prevalence of NAFLD established by hepatic ultrasound and biopsy studies.

The clinical practical implication is that an ALT of 35 U/L — clearly within the standard 40 U/L reporting cutoff — should not be reflexively dismissed as "normal," especially in a woman or in a patient with metabolic risk factors. The 2017 ACG Clinical Guideline (Kwo et al.) explicitly endorses the Prati cutoffs for clinical decision-making in the workup of liver disease, even when the local laboratory continues to report up to 40 U/L as "normal."

For patients tracking their own liver health, the practical rule of thumb is:

Back to Table of Contents

Interpretation by Magnitude of ALT Elevation

The magnitude of ALT elevation correlates roughly with the type of underlying liver pathology, providing a useful clinical heuristic:

The rate of change of ALT is also informative. Acute hepatitis typically rises over days and then falls predictably as the injury resolves. Chronic liver disease typically shows stable mildly-elevated values over months. A sudden rise in a previously stable ALT prompts workup for a new injury (drug, infection, ischemic event).

Back to Table of Contents

The AST:ALT Ratio — Alcoholic vs Non-Alcoholic Patterns

The ratio of AST to ALT (often written as AST/ALT or De Ritis ratio after the Italian biochemist who first proposed it in 1957) provides important diagnostic information about the underlying liver process:

The Williams-Hoofnagle 1988 Gastroenterology paper expanded the diagnostic value of the AST:ALT ratio specifically for cirrhosis assessment: as liver disease progresses from chronic active inflammation to cirrhosis, the AST:ALT ratio rises regardless of the original etiology. A NASH patient who starts with AST:ALT of 0.7 may have AST:ALT of 1.4 by the time NASH-related cirrhosis develops. This makes serial AST:ALT trending useful for monitoring chronic liver disease progression.

The clinical use of the De Ritis ratio is therefore twofold: (1) initial differential diagnosis of acute or chronic liver disease (alcoholic vs non-alcoholic, principally), and (2) monitoring chronic liver disease progression toward cirrhosis. Both uses are based on the same biochemistry — the differential B6-cofactor dependence of ALT vs AST, modulated by the underlying disease's effect on hepatic protein synthesis.

Back to Table of Contents

NAFLD — The Global Liver Disease Epidemic

Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic-dysfunction-associated steatotic liver disease (MASLD) in the 2023 multi-society consensus, has become the leading cause of chronic liver disease worldwide. The Younossi 2016 Hepatology meta-analysis estimated global prevalence at approximately 25% of adults, with substantial regional variation: about 32% in South America, 27% in Asia, 24% in North America, 24% in Europe, and 31% in the Middle East. In the United States, the National Health and Nutrition Examination Survey (NHANES) data suggest that 30-40% of adults have hepatic steatosis on imaging, of whom an estimated 5-10% have progressed to the more severe non-alcoholic steatohepatitis (NASH) with active inflammation and fibrosis.

NAFLD/MASLD is best understood as the hepatic manifestation of metabolic syndrome — the cluster of central obesity, insulin resistance, atherogenic dyslipidemia, hypertension, and type 2 diabetes that has become the dominant chronic disease pattern in developed and rapidly developing economies. The pathophysiology involves:

  1. Excess hepatic fatty acid delivery — from dietary fat, from de novo lipogenesis driven by chronic hyperinsulinemia, and from accelerated lipolysis of insulin-resistant visceral adipose tissue. The hepatocyte's capacity to package and export triglyceride as VLDL is exceeded.
  2. Hepatic triglyceride accumulation — visible as macrovesicular steatosis on biopsy and as hepatic steatosis on ultrasound, CT, or MRI elastography.
  3. Lipotoxicity-induced hepatocyte injury — the accumulated free fatty acids, diacylglycerols, and ceramides activate inflammatory cytokine production and apoptotic pathways. Cell death releases ALT into the circulation.
  4. Hepatic stellate cell activation — the wound-healing response to chronic hepatocyte injury produces collagen deposition and progressive fibrosis. Over years to decades, this can progress to cirrhosis.

ALT elevation is the most accessible biochemical signal of this process, but ALT has poor sensitivity for NAFLD. The Mofrad 2003 study famously documented histologically severe NAFLD with normal ALT values in approximately 20% of NAFLD patients. The implication is that a normal ALT does not exclude NAFLD — imaging (ultrasound, MRI-PDFF, or transient elastography) is needed when the clinical suspicion is high (BMI > 30, type 2 diabetes, metabolic syndrome features).

Management of NAFLD is currently behavioral and pharmacological:

For more on NAFLD, see our pages on Metabolic Syndrome and Liver Disease.

Back to Table of Contents

Drug-Induced Liver Injury (DILI)

Drug-induced liver injury is the most common cause of acute liver failure in the developed world and a frequent cause of elevated ALT. Hundreds of medications and herbal products have been implicated. The patterns of injury fall into three principal categories:

Specific medications worth knowing:

The standard approach to suspected DILI is the modified Roussel-Uclaf Causality Assessment Method (RUCAM), which scores the temporal relationship, exclusion of other causes, risk factors, response to dechallenge, and prior knowledge of hepatotoxicity to estimate the probability that a specific agent caused the observed injury.

Back to Table of Contents

Viral Hepatitis Pattern

Viral hepatitis remains an important cause of ALT elevation worldwide. The clinical context and serology determine the workup:

The standard initial viral panel for an unexplained ALT elevation is HBsAg, anti-HCV, and (in appropriate clinical settings) anti-HAV IgM and anti-HIV.

Back to Table of Contents

Practical Workup of an Isolated ALT Elevation

The Kwo 2017 ACG Clinical Guideline and the Newsome 2018 BSG guideline both provide structured approaches to the patient with an isolated ALT elevation. A practical synthesis:

  1. Confirm and characterize — repeat the LFTs to ensure the elevation is real and not laboratory artifact. Calculate the AST:ALT ratio and the R-value (ALT/ULN ÷ ALP/ULN). Check INR and albumin for synthetic function assessment.
  2. History — alcohol intake (use AUDIT-C), medication and herbal supplement use, IV drug use risk factors, sexual risk factors, travel history, family history of liver disease, occupational exposures, prior episodes of jaundice, autoimmune disease history.
  3. Physical examination — BMI and waist circumference (metabolic syndrome), stigmata of chronic liver disease (palmar erythema, spider angiomata, gynecomastia, ascites, splenomegaly), Kayser-Fleischer rings (Wilson disease), arthritis (autoimmune hepatitis association).
  4. First-tier laboratory workup — metabolic panel (fasting glucose, A1c, lipid panel for NAFLD risk stratification), HBsAg, anti-HCV, ferritin and transferrin saturation (hemochromatosis), ANA and ASMA (autoimmune hepatitis), tissue transglutaminase IgA (celiac).
  5. Imaging — abdominal ultrasound for hepatic steatosis, biliary tree, and any focal lesions. MRI-PDFF if quantitative steatosis assessment is needed. Transient elastography (FibroScan) if fibrosis assessment is needed (NAFLD >F2 fibrosis is a hepatology referral trigger).
  6. Second-tier workup if first-tier negative — ceruloplasmin and 24-hour urinary copper (Wilson disease), alpha-1 antitrypsin level and Pi typing (alpha-1 antitrypsin deficiency), thyroid function (hypothyroidism-associated NAFLD), HIV testing, repeat viral hepatitis panel including HEV in appropriate clinical contexts.
  7. Specialty referral — ALT > 5x ULN despite negative initial workup; persistent ALT elevation >6 months without identified cause; any patient with cirrhosis or significant fibrosis (NAFLD >F2); fulminant presentation (rising INR, encephalopathy, jaundice).
  8. Liver biopsy — rarely needed in modern hepatology due to advances in non-invasive imaging and serological scoring. Indicated when the diagnosis remains unclear after the second-tier workup, or when management decisions require histological staging.

The most common ultimate diagnosis for an isolated mildly-elevated ALT in a developed-world primary care population is NAFLD, followed by chronic viral hepatitis (B or C), alcoholic liver disease, drug-induced injury, and autoimmune hepatitis. The rarer diagnoses (Wilson disease, alpha-1 antitrypsin deficiency, hemochromatosis) should be specifically considered in younger patients without obvious metabolic or behavioral risk factors.

Back to Table of Contents

The Alanine Load Test for Hepatic Function

The alanine load test is a research-grade assessment of hepatic functional reserve that uses an oral alanine dose (15-30 g) to challenge the gluconeogenic capacity of the liver. The post-load plasma glucose and alanine kinetics provide a sensitive measure of hepatic gluconeogenic capacity that is impaired earlier than conventional liver function markers.

In healthy subjects, oral alanine produces a brisk rise in plasma alanine peaking at 60-90 minutes, with proportional plasma glucose rise and glucagon secretion. The plasma alanine clearance half-life is approximately 90 minutes. The test was originally developed by Genuth and Castro in the 1970s for assessing fasting and obesity physiology, and subsequently adapted for research evaluation of hepatic function in cirrhosis, NASH, and post-bariatric patients.

The alanine load test is rarely used in routine clinical hepatology because non-invasive imaging (MRI elastography, FibroScan) and validated scoring systems (FIB-4, NAFLD Fibrosis Score, APRI) provide more practical assessments of hepatic function and fibrosis. The test remains useful in research settings where dynamic gluconeogenic capacity is the specific question of interest.

For patients curious about alanine's metabolic role in their own physiology, the clinical correlate is simpler: a standard glucose tolerance test (oral 75 g glucose with serial glucose and insulin measurements) implicitly assesses the post-load alanine response as part of the integrated postprandial metabolic state. Reactive hypoglycemia identified on a glucose tolerance test often reflects impaired alanine-mediated gluconeogenic counter-regulation.

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Pratt DS, Kaplan MM (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. NEJM 342(17):1266-1271. — DOI: 10.1056/NEJM200004273421707
  2. Prati D, Taioli E, Zanella A, et al. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine 137(1):1-10. — DOI: 10.7326/0003-4819-137-1-200207020-00006
  3. Kwo PY, Cohen SM, Lim JK (2017). ACG Clinical Guideline: Evaluation of abnormal liver chemistries. American Journal of Gastroenterology 112(1):18-35. — DOI: 10.1038/ajg.2016.517
  4. Newsome PN, Cramb R, Davison SM, et al. (2018). Guidelines on the management of abnormal liver blood tests. Gut 67(1):6-19. — DOI: 10.1136/gutjnl-2017-314924
  5. Younossi ZM, Koenig AB, Abdelatif D, et al. (2016). Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment. Hepatology 64(1):73-84. — DOI: 10.1002/hep.28431
  6. Cohen JC, Horton JD, Hobbs HH (2011). Human fatty liver disease: old questions and new insights. Science 332(6037):1519-1523. — DOI: 10.1126/science.1204265
  7. Mofrad P, Contos MJ, Haque M, et al. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37(6):1286-1292. — DOI: 10.1053/jhep.2003.50229
  8. Williams ALB, Hoofnagle JH (1988). Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis — relationship to cirrhosis. Gastroenterology 95(3):734-739. — DOI: 10.1016/0016-5085(88)90192-1
  9. Cohen JA, Kaplan MM (1979). The SGOT/SGPT ratio — an indicator of alcoholic liver disease. Digestive Diseases and Sciences 24(11):835-838. — DOI: 10.1007/BF01324898
  10. Sookoian S, Pirola CJ (2012). Alanine and aspartate aminotransferase and glutamine-cycling pathway in NAFLD. World Journal of Gastroenterology 18(29):3775-3781. — DOI: 10.3748/wjg.v18.i29.3775
  11. Cohen DE, Anania FA, Chalasani N (2006). An assessment of statin safety by hepatologists. American Journal of Cardiology 97(8A):77C-81C. — DOI: 10.1016/j.amjcard.2005.12.010
  12. Larson AM, Polson J, Fontana RJ, et al. (2005). Acetaminophen-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 42(6):1364-1372. — DOI: 10.1002/hep.20948
  13. Chalasani N, Younossi Z, Lavine JE, et al. (2018). The diagnosis and management of NAFLD: practice guidance from AASLD. Hepatology 67(1):328-357. — DOI: 10.1002/hep.29367
  14. Genuth SM, Castro J (1974). Effect of oral alanine administration in fasting obese subjects. Metabolism 23(4):375-386. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents